KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Basic) (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of EPS (Basic) data on record, last reported at -$1.57 in Q3 2025.

  • For Q3 2025, EPS (Basic) rose 40.98% year-over-year to -$1.57; the TTM value through Sep 2025 reached -$2.11, up 69.06%, while the annual FY2024 figure was -$0.58, 60.0% up from the prior year.
  • EPS (Basic) reached -$1.57 in Q3 2025 per NKTR's latest filing, up from -$6.33 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $6.03 in Q4 2024 and bottomed at -$6.33 in Q2 2025.
  • Average EPS (Basic) over 5 years is -$0.79, with a median of -$0.68 recorded in 2021.
  • The widest YoY moves for EPS (Basic): up 2971.43% in 2024, down 1292.59% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.79 in 2021, then surged by 59.49% to -$0.32 in 2022, then soared by 34.38% to -$0.21 in 2023, then surged by 2971.43% to $6.03 in 2024, then tumbled by 126.04% to -$1.57 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$1.57 in Q3 2025, -$6.33 in Q2 2025, and -$0.24 in Q1 2025.